SCHEMBL6236981

SCHEMBL6236981

CCOC(=O)CC(=O)c1ccc(F)c(OC)c1OCC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.48
ALDH1A1 P00352 3/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
PDE4D Q08499 1/20 0.39
MIF P14174 1/20 0.38
NLRP3 Q96P20 1/20 0.37
MGAM O43451 1/20 0.37
GAA P10253 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
MGLL Q99685 1/20 0.35
LMNA P02545 2/20 0.35
CYP1A2 P05177 1/20 0.35
MAPT P10636 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
PKM P14618 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2601626 0.89 MEN1 (0.50) KDM4EALDH1A1MEN1KMT2AMIF
SCHEMBL116517 0.86 MEN1 (0.50) KDM4EALDH1A1MEN1KMT2AMIF
SCHEMBL6239436 0.83 ALDH1A1 (0.50) KDM4EALDH1A1MEN1KMT2AMIF
SCHEMBL312535 0.80 CES2 (0.47) KDM4EALDH1A1MEN1KMT2AMIF
SCHEMBL10565488 0.77 MEN1 (0.60) KDM4EALDH1A1MEN1KMT2APDE4D
SCHEMBL589507 0.76 KMT2A (0.51) KDM4EALDH1A1MEN1KMT2AMIF
SCHEMBL30181119 0.75 ALDH1A1 (0.54) KDM4EALDH1A1MEN1KMT2AMIF
SCHEMBL966496 0.75 ALDH1A1 (0.54) KDM4EALDH1A1MEN1KMT2AMIF
SCHEMBL1555005 0.75 CPS1 (0.50) KDM4EALDH1A1MEN1KMT2AGAA
SCHEMBL31493199 0.75 CPS1 (0.50) KDM4EALDH1A1MEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1532114-A2 PROCESS FOR PREPARING QUINOLONE ANTIBIOTIC INTERMEDIATES THE PROCTER & GAMBLE COMPANY (US) 2005-05-25 EP disclosed
US-6803469-B2 CYCLIZING IN THE PRESENCE OF A SILYLATING AGENT THE PROCTER & GAMBLE COMPANY 2004-10-12 US disclosed
US-20040063952-A1 Process for preparing quinolone antibiotic intermediates WARNER CHILCOTT COMPANY, LLC 2004-04-01 US disclosed
WO-2004013103-A2 PROCESS FOR PREPARING QUINOLONE ANTIBIOTIC INTERMEDIATES THE PROCTER & GAMBLE COMPANY (US) 2004-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063952-A1 Process for preparing quinolone antibiotic intermediates QPCT, CCNT1, TOP1 KDM4E 1114/4885ALDH1A1 751/4885MEN1 1557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.